Oaktree Capital Management Provides $100MM in Financing to Impel Neuropharma
Oaktree Capital Management closed two separate transactions totaling $100 million in gross funding for Impel NeuroPharma, a commercial-stage pharmaceutical company. The transactions include $50 million of senior secured debt.
March 18, 2022
Adrian Adams | Aman Kumar | Impel NeuroPharma | Oaktree Capital Management
Phil Neuffer